EMD-10463

Single-particle
3.2 Å
EMD-10463 Deposition: 07/11/2019
Map released: 26/08/2020
Last modified: 01/10/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-10463

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-6td5 summary report (pdf.gz) Map-6td5 FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

Leishmania tarentolae proteasome 20S subunit complexed with LXE408 and bortezomib

EMD-10463

Single-particle
3.2 Å
EMD-10463 Deposition: 07/11/2019
Map released: 26/08/2020
Last modified: 01/10/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Leishmania donovani
Sample: Leishmania tarentolae proteasome 20S subunit complexed with LXE408 and bortezomib
Fitted models: 6td5

Deposition Authors: Srinivas H
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.
PUBMED: 32667203
DOI: doi:10.1021/acs.jmedchem.0c00499
ISSN: 0022-2623
ASTM: JMCMAR